

A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA

NCT05820672

Status RECRUITING
Sponsor Ascendis Pharma Endocrinology Division A/S
Enrollment 900 participants

Key Eligibility Criteria

Inclusion (3)

- Patients who are on treatment with SKYTROFA (lonapegsomatropin)
- Patients being clinically managed in USA
- Patients with an appropriate written informed consent/assent as applicable for the age of the patient

Exclusion (1)

- Patients participating in any interventional clinical study

Locations (27 total)

Ascendis Investigational Site, Phoenix, Arizona, United States
Ascendis Investigational Site, Orange, California, United States
Ascendis Investigational Site, Sacramento, California, United States
... and 24 more locations